'Tibsovo,' a targeted anticancer drug for cholangiocarcinoma and acute myeloid leukemia (AML), is now available for prescription in general hospitals.

According to industry sources, Servier's Tibsovo (ivosidenib), a drug targeting the isocitrate Dehydrogenase 1 (IDH-1) gene mutation, has passed the drug committees (DC) of the 'Big 5' tertiary general hospitals, including Samsung Medical Center, Seoul National University Hospital, and Seoul Asan Medical Center, and medical centers, including, Gangnam Severance Hospital, National Cancer Center, Gangnam Severance Hospital, and Chungbuk National University Hospital.

Following receiving approval from the Ministry of Food and Drug Safety (MFDS